The experimental analysis confirmed copy number gain in MTC samples as compared to their paired blood sample for the three regions encompassing the genes SNORD116-18, DLK1 and AIFM3. The other three regions, comprising the genes FGF7P3 and ADAM8 or containing no gene, were not validated in this initial validation step, and therefore, were excluded from further analysis. This evidence concerns the gene AIFM3 and medullary thyroid gland carcinoma.